Remove Capital Remove Document Remove Pricing Remove San Diego
article thumbnail

San Diego's Seismic Snags $100M, Joins Unicorns

socalTECH

San Diego-based Seismic , a developer of sales and marketing software, has raised $100M more in a funding round, which values the company at $1 billion, the company said on Tuesday. Rowe Price, plus General Atlantic, JMI Equity, and Jackson Square Ventures. The funding round came from Lightspeed Venture Partners, T.

San Diego 113
article thumbnail

Silvergate Bank Files for IPO to Grow Cryptocurrency Services

Xconomy

On Tuesday it set a $50 million price target, according to documents filed with securities regulators. Silvergate Bank has transformed itself in recent years from a typical business bank to one of the financial institutions of choice for digital currency companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bio Roundup: Trump’s Budget, Biogen’s AD Reveal, Hugin’s Run & More

Xconomy

There was talk of tackling high drug prices in the budget document, but nothing to give Medicare direct negotiating power with drug companies or allow importation of cheaper drugs from other countries—ideas Trump has embraced on occasion.

Pricing 57
article thumbnail

Biotech Roundup: CRISPR’s 3rd IPO, Gender Diversity, Buyouts & More

Xconomy

New documents came to light that showed the sugar industry paid for studies downplaying the ties between sugar and heart disease. Our presidential candidates were either recovering from pneumonia or talking up their health records. million from Polaris Partners and other unnamed investors.

article thumbnail

Bio Roundup: Clinical Shirkers, AMD Worriers, ASH Fallers & More

Xconomy

Its owner Pfizer (NYSE: PFE ) shelved it this week , citing poor Phase 3 data and pricing pressures on the two approved PCSK9 drugs. . —The new wave of so-called PCSK9 drugs to treat high cholesterol, once expected to flood the market , have barely caused a ripple. One latecomer, bococizumab, won’t even reach approval.